New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
07:43 EDTOHRPOhr Pharmaceutical weakness a buying opportunity, says Brean Capital
Brean Capital said the weakness in Ohr Pharmaceutical due to investors concerns surrounding insufficient dosing for its AMD trials should be used as a buying opportunity. The firm believes the concerns are overblown and that short sellers and a weak biotech sector are driving the price lower. Shares remain Buy rated with a $21 price target.
News For OHRP From The Last 14 Days
Check below for free stories on OHRP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for OHRP

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use